nicergoline has been researched along with Alzheimer Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bogolepova, AN | 1 |
| Abe, K; Hishikawa, N; Matsumoto, N; Nomura, E; Ohta, Y; Omote, Y; Sasaki, R; Tadokoro, K; Takemoto, M; Tsunoda, K; Yamashita, T | 1 |
| Weinstein, JD | 1 |
| Chen, L; Fang, L; Wang, C; Zang, G | 1 |
| Damulin, IV | 1 |
| Battaglia, A; Battaglia, G; Bosco, P; Calafiore, M; Canonico, PL; Caraci, F; Chisari, M; Copani, A; Frasca, G; Nicoletti, F; Sortino, MA | 1 |
| Anderer, P; Grünberger, J; Linzmayer, L; Neuhold, A; Paulus, E; Podreka, I; Saletu, B; Semlitsch, HV; Wicke, L | 1 |
| Winblad, B | 1 |
| Crook, TH | 1 |
| Anderer, P; Saletu, B; Semlitsch, HV | 1 |
| Flynn, BL; Ranno, AE | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Arnetoli, G; Battaglia, A; Grignani, A; Paganini, M; Sacchetti, G; Versari, A; Zappoli, R | 1 |
3 review(s) available for nicergoline and Alzheimer Disease
| Article | Year |
|---|---|
[Dementia and small vessel diseases of the brain].
Topics: Alzheimer Disease; Brain; Cerebral Small Vessel Diseases; Dementia, Vascular; Humans; Neuroimaging; Nicergoline; Risk Factors | 2014 |
Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives.
Topics: Alzheimer Disease; Antihypertensive Agents; Antioxidants; Drugs, Investigational; Ergoloid Mesylates; Humans; Nicergoline; Nootropic Agents | 1999 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
4 trial(s) available for nicergoline and Alzheimer Disease
| Article | Year |
|---|---|
The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Apathy; Citalopram; Depression; Female; Humans; Male; Nicergoline; Nootropic Agents; Prospective Studies; Sertraline; Single-Blind Method; Treatment Outcome | 2020 |
Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.
Topics: Alzheimer Disease; Brain; Brain Mapping; Dementia, Multi-Infarct; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Humans; Male; Nicergoline; Psychiatric Status Rating Scales | 1995 |
Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Dementia, Multi-Infarct; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Mental Status Schedule; Nicergoline | 1997 |
Contingent negative variation and reaction time in patients with presenile idiopathic cognitive decline and presenile Alzheimer-type dementia. Preliminary report on long-term nicergoline treatment.
Topics: Alzheimer Disease; Cognition Disorders; Contingent Negative Variation; Double-Blind Method; Electroencephalography; Electrophysiology; Ergolines; Female; Humans; Male; Middle Aged; Nicergoline; Reaction Time | 1987 |
7 other study(ies) available for nicergoline and Alzheimer Disease
| Article | Year |
|---|---|
[Vascular cognitive impairment].
Topics: Alzheimer Disease; Cholinergic Agents; Cognitive Dysfunction; Dementia, Vascular; Humans; Nicergoline; Stroke | 2022 |
A unique and promising combination of medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Dementia; Disease Progression; Drug Design; Drug Therapy, Combination; Humans; Inflammation; Methylene Blue; Neurons; Nicergoline; Oxidative Stress; Pentoxifylline; Pyridoxamine; Pyrimidines | 2017 |
Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Hippocampus; Male; Mice; Neurogenesis; Neuroprotective Agents; Nicergoline; Nootropic Agents; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Signal Transduction | 2018 |
Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Astrocytes; bcl-2-Associated X Protein; Cell Communication; Cells, Cultured; Cerebral Cortex; Coculture Techniques; Cognition Disorders; Memory Disorders; Nerve Growth Factors; Neurons; Neuroprotective Agents; Nicergoline; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley | 2005 |
[Therapy of primary dementia based on modern concepts].
Topics: Adrenergic alpha-Antagonists; Alzheimer Disease; Dementia; Dementia, Multi-Infarct; Humans; Nicergoline | 1995 |
Altered neurotransmission and signal transduction: targets for nicergoline treatment.
Topics: Adrenergic alpha-Antagonists; Alzheimer Disease; Cyclic AMP; Humans; Neurotransmitter Agents; Nicergoline; Signal Transduction | 1997 |
Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias.
Topics: Adrenergic alpha-Antagonists; Alzheimer Disease; Clinical Trials as Topic; Dementia; Drug Evaluation; Humans; Mental Status Schedule; Nicergoline; Treatment Outcome | 1997 |